The efficacy of dabrafenib as monotherapy, or in combination with other drugs, has also been investigated in a phase-II clinical trial involving 84 BRAF (exon 15 p.V600E)-positive NSCLC patients. Here, BRAF is linked to non-small cell lung carcinoma.